Overview

Correlation Between Change of HbA1c, Urinary Glucose Excretion and Other Factors in Patients Treated With Ipragliflozin

Status:
Completed
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the correlation between change of HbA1c, urinary glucose excretion and other factors when ipragliflozin is added to preexisting therapy in subjects with type 2 diabetes.
Phase:
Phase 4
Details
Lead Sponsor:
Asan Medical Center
Collaborators:
Astellas Pharma Korea, Inc.
Kyung Hee University Hospital at Gangdong
Samsung Medical Center
Severance Hospital
Treatments:
Ipragliflozin